Roche/Genentech in-licenses Bicycle Therapeutics TKI assets"By leveraging Genentech's deep understanding of cancer immunology and Bicycle's technological expertise, we hope to create a new wave of immunotherapy options to expand the population of patients who could potentially benefit from this powerful treatment paradigm," James Sabry, the head of pharma partnering at Roche commented in an earlier press release."
https://www.biospace.com/article/genentech-partners-with-chinese-biopharma-for-prostate-cancer-androgen-receptor-degrader/
[ Bicycle's tyrosine kinase inhibitor (TKI) is in the form of an EphA2 toxin conjugate (anti-body drug conjugate/ADC), since EphA2 is a member of the Ephrin superfamily of tyrosine kinases.
Examples of EphA2 expressing tumors are NSCLC, TNBC, Bladder Cancer, Gastric Cancer and Ovarian Cancer, which are being addressed through ONCY's Goblet-1 study in GI cancers. ]
https://www.bicycletherapeutics.com/programs/bicycle-conjugates/